Results 131 to 140 of about 31,967 (178)

Interstrain recombinants of human cytomegalovirus uncouple glycoprotein display, virion infectivity, and spread characteristics. [PDF]

J Virol
Peterson CS, Bailey IT, Lanchy J-M, Gallego I, Ryckman BJ.   +4 more
europepmc   +1 more source

Repurposing of the bisbenzimide antibiotic Ridinilazole as an antiviral compound against human cytomegalovirus. [PDF]

J Gen Virol
Pinto H, Latham KA, Goodbourn S, Witney AA, Strang BL.   +4 more
europepmc   +1 more source

Optimizing delivery of an anti-cytomegalovirus inhibitory peptide using a cell-penetrating peptide. [PDF]

J Gen Virol
Beeton K, Haskell JP, Mitra D, Taylor EB, Bidwell GL.   +4 more
europepmc   +1 more source

Cross-herpesvirus immunity of the cytomegalovirus gB/MF59 vaccine response. [PDF]

NPJ Vaccines
Lankina A, Hargreaves A, Lui WT, Kropff B, Wei A, Breuer J, White RE, Thomas M, Griffiths PD, Reeves MB.   +9 more
europepmc   +1 more source

Retraction: The Downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 Axis and by Human Cytomegalovirus (HCMV) Associated Factors Allows the Activation of the HCMV Major IE Promoter and the Transition to Productive Infection. [PDF]

PLoS Pathog
PLOS Pathogens Editors.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Human cytomegalovirus (HCMV) long-term shedding and HCMV-specific immune response in pregnant women with primary HCMV infection

Medical Microbiology and Immunology, 2022
Human cytomegalovirus (HCMV) shedding has been extensively investigated in newborns and in young children, however, much less is known about it in immunocompetent adults. Shedding of HCMV was investigated in saliva, vaginal secretions and urine of pregnant women experiencing primary infection along with the development of the HCMV-specific immune ...
C. Fornara, F. Zavaglio, M. Furione, A. Sarasini, P. d’Angelo, A. Arossa, A. Spinillo, D. Lilleri, F. Baldanti   +8 more
openaire   +3 more sources

Models of HCMV latency and reactivation

Trends in Microbiology, 2003
Human cytomegalovirus (HCMV) is a ubiquitous β-herpesvirus that causes severe disease primarily in immunosuppressed individuals. A major characteristic of HCMV, with obvious clinical importance, is its ability to establish lifelong infection within the host following the initial acute infection.
Daniel N, Streblow, Jay A, Nelson
openaire   +2 more sources

Adoptive immunotherapy of HCMV infection

Cytotherapy, 2007
Human cytomegalovirus (HCMV) infection or reactivation is a frequent cause of morbidity and mortality in immunocompromised individuals such as transplant recipients. Primary HCMV infection or reactivation of HCMV from latency is mostly asymptomatic in immunocompetent individuals and is controlled by the host's cell-mediated immune response.
M, Kapp, S M, Tan, H, Einsele, Gu, Grigoleit   +3 more
openaire   +2 more sources

Methods in Anti-HCMV Research

2003
The study of strategies for the treatment of human cytomegalovirus (HCMV) infection starts with the discovery of compounds that are potent and selective inhibitors of HCMV replication. Selectivity means that the window between the concentrations that block viral replication on the one hand and those that affect host cell functions on the other is ...
J, Neyts, G, Andrei, R, Snoeck, A, Meerbach, E, De Clercq   +4 more
openaire   +2 more sources